Zacks Research Issues Optimistic Forecast for NKTR Earnings

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Research analysts at Zacks Research increased their Q2 2025 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research note issued to investors on Wednesday, June 18th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.19) for the quarter, up from their prior forecast of ($2.85). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics' Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.79) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($0.98) EPS, Q1 2027 earnings at ($0.26) EPS and FY2027 earnings at ($1.23) EPS.

Several other equities research analysts have also recently commented on NKTR. Wall Street Zen cut Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and lifted their target price for the company from $15.00 to $30.00 in a research note on Friday, April 11th. Oppenheimer raised Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 target price for the company in a research note on Friday, March 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $97.50 target price on shares of Nektar Therapeutics in a research note on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $67.50.

Nektar Therapeutics Price Performance

NKTR stock opened at $8.51 on Monday. The business has a fifty day moving average price of $10.08 and a 200 day moving average price of $11.88. The stock has a market capitalization of $105.61 million, a price-to-earnings ratio of -0.89 and a beta of 0.55. Nektar Therapeutics has a fifty-two week low of $6.48 and a fifty-two week high of $22.79.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. The business had revenue of $10.46 million for the quarter, compared to analyst estimates of $15.61 million. During the same period in the prior year, the business earned ($2.70) earnings per share.

Institutional Investors Weigh In On Nektar Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new stake in Nektar Therapeutics in the 4th quarter valued at approximately $130,000. Wellington Management Group LLP raised its position in Nektar Therapeutics by 10.4% in the 4th quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company's stock valued at $486,000 after buying an additional 49,319 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in Nektar Therapeutics by 267.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 175,193 shares of the biopharmaceutical company's stock valued at $163,000 after buying an additional 127,459 shares during the last quarter. Ameriprise Financial Inc. raised its position in Nektar Therapeutics by 32.8% in the 4th quarter. Ameriprise Financial Inc. now owns 373,948 shares of the biopharmaceutical company's stock valued at $348,000 after buying an additional 92,346 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Nektar Therapeutics by 26.5% in the 4th quarter. Wells Fargo & Company MN now owns 108,975 shares of the biopharmaceutical company's stock valued at $101,000 after buying an additional 22,822 shares during the last quarter. Institutional investors and hedge funds own 75.88% of the company's stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.